Sequence- and target-independent angiogenesis suppression by siRNA via TLR3

Nature

Volumn 452, Issue 7187, 2008, Pages 591-597

  Kleinman, Mark E ^a   Yamada, Kiyoshi ^a   Takeda, Atsunobu ^a   Chandrasekaran, Vasu ^c   Nozaki, Miho ^a   Baffi, Judit Z ^a   Albuquerque, Romulo J C ^a,b   Yamasaki, Satoshi ^d   Itaya, Masahiro ^d   Pan, Yuzhen ^e   Appukuttan, Binoy ^e   Gibbs, Daniel ^f   Yang, Zhenglin ^f   Karikó, Katalin ^g   Ambati, Balamurali K ^f,h   Wilgus, Traci A ⁱ   DiPietro, Luisa A ⁱ   Sakurai, Eiji ^d   Zhang, Kang ^f   Smith, Justine R ^e   Taylor, Ethan W ^j   Ambati, Jayakrishna ^a,b   more..

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^j UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 12; NUCLEOTIDE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

CARDIOVASCULAR SYSTEM; DISEASE TREATMENT; GENE EXPRESSION; INHIBITION; PROTEIN; RNA; RODENT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL SURFACE; CYTOTOXICITY; DRUG MECHANISM; ENDOTHELIUM CELL; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC VARIABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SUBRETINAL NEOVASCULARIZATION;

MAMMALIA; MUS;

EID: 41649115210     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature06765     Document Type: Article

References (55)

1. Chiu, Y. L., Ali, A., Chu, C. Y., Cao, H. & Rana, T. M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11, 1165-1175 (2004).
2. Saleh, M. C. et al. The endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing. Nature Cell Biol. 8, 793-802 (2006).
3. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
4. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23, 709-717 (2005).
5. Reich, S. J. et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210-216 (2003).
6. Shen, J. et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 13, 225-234 (2006).
7. Krzystolik, M. G. et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120, 338-346 (2002).
8. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006).
9. Corey, D. R. RNA learns from antisense. Nature Chem. Biol. 3, 8-11 (2007).
10. de Fougerolles, A., Vornlocher, H. P., Maraganore, J. & Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nature Rev. Drug Discov. 6, 443-453 (2007).
11. Rana, T. M. Illuminating the silence: understanding the structure and function of small RNAs. Nature Rev. Mol. Cell Biol. 8, 23-36 (2007).
12. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol. 21, 635-637 (2003).
13. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnol. 25, 1149-1157 (2007).
14. Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732-738 (2001).
15. Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165-175 (2005).
16. Bell, J. K. et al. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc. Natl Acad. Sci. USA 102, 10976-10980 (2005).
17. Ranjith-Kumar, C. T. et al. Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain. J. Biol. Chem. 282, 7668-7678 (2007).
18. Lee, H. K., Dunzendorfer, S., Soldau, K. & Tobias, P. S. Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 24, 153-163 (2006).
19. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301, 640-643 (2003).
20. Hoebe, K. et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424, 743-748 (2003).
21. Jiang, Z., Mak, T. W., Sen, G. & Li, X. Toll-like receptor 3-mediated activation of NF-κB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-β. Proc. Natl Acad. Sci. USA 101, 3533-3538 (2004).
22. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnol. 23, 457-462 (2005).
23. Hornung, V. et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263-270 (2005).
24. Judge, A. D., Bola, G., Lee, A. C. & MacLachlan, I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505 (2006).
25. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
26. Meurs, E. et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62, 379-390 (1990).
27. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 5, 730-737 (2004).
28. Gitlin, L. et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103, 8459-8464 (2006).
29. Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H. & Williams, B. R. Activation of the interferon system by short-interfering RNAs. Nature Cell Biol. 5, 834-839 (2003).
30. Gowen, B. B. et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol. 178, 5200-5208 (2007).
31. Heidel, J. D., Hu, S., Liu, X. F., Triche, T. J. & Davis, M. E. Lack of interferon response in animals to naked siRNAs. Nature Biotechnol. 22, 1579-1582 (2004).
32. Kariko, K., Bhuyan, P., Capodici, J. & Weissman, D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172, 6545-6549 (2004).
33. Kim, D. H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nature Biotechnol. 22, 321-325 (2004).
34. Voest, E. E. et al. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl Cancer Inst. 87, 581-586 (1995).
35. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl Acad. Sci. USA 95, 9349-9354 (1998).
36. Nozaki, M. et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J. Clin. Invest. 116, 422-429 (2006).
37. Nykanen, A., Haley, B. & Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107, 309-321 (2001).
38. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-574 (2002).
39. Birmingham, A. et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nature Methods 3, 199-204 (2006).
40. Battle, T. E., Lynch, R. A. & Frank, D. A. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 66, 3649-3657 (2006).
41. Bell, J. K., Askins, J., Hall, P. R., Davies, D. R. & Segal, D. M. The dsRNA binding site of human Toll-like receptor 3. Proc. Natl Acad. Sci. USA 103, 8792-8797 (2006).
42. Choe, J., Kelker, M. S. & Wilson, I. A. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 309, 581-585 (2005).
43. Gay, N. J., Gangloff, M. & Weber, A. N. Toll-like receptors as molecular switches. Nature Rev. Immunol. 6, 693-698 (2006).
44. Takada, E. et al. C-terminal LRRs of human Toll-like receptor 3 control receptor dimerization and signal transmission. Mol. Immunol. 44, 3633-3640 (2007).
45. Ranjith-Kumar, C. T. et al. Effects of single nucleotide polymorphisms on Toll-like Receptor 3 activity and expression in cultured cells. J. Biol. Chem. 282, 17696-17705 (2007).
46. Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53-67 (2007).
47. Nozaki, M. et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl Acad. Sci. USA 103, 2328-2333 (2006).
48. Lin, Y., Liang, Z., Chen, Y. & Zeng, Y. TLR3-involved modulation of pregnancy tolerance in double-stranded RNA-stimulated NOD/SCID mice. J. Immunol. 176, 4147-4154 (2006).
49. Lang, K. S. et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 116, 2456-2463 (2006).
50. Cameron, J. S. et al. Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. J. Neurosci. 27, 13033-13041 (2007).
51. Muller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 264, 1918-1921 (1994).
52. Sato, M. et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-α/β gene induction. Immunity 13, 539-548 (2000).
53. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 3, 196-200 (2002).
54. Zhang, L. et al. Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem. Biophys. Res. Commun. 292, 860-868 (2002).
55. Smith, J. R. et al. Unique gene expression profiles of donor-matched human retinal and choroidal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 48, 2676-2684 (2007).